Fraunhofer IMM, part of the globally renowned Fraunhofer-Gesellschaft, today announced the signing of a Memorandum of Understanding (MoU) with CATUG, Basel, Switzerland. This strategic collaboration will drive joint research and development initiatives, particularly in the fields of nucleic acids and nanoparticle technology. CATUG is a pioneering contract service provider in RNA therapeutics and LNP formulations. The collaboration between Fraunhofer IMM and CATUG will leverage their combined expertise in sustainable technologies, scalable nanoformulation systems, and advanced nanoanalytics. Together, the partnership aims to accelerate innovation in therapeutic solutions, particularly in RNA and lipid nanoparticle (LNP) formulations.
more info